RxDoctor Payments Data

Julia Ellingwood

Family · Fort Wayne, INNPI 1790199255

Payments from drug & device makers

$10,933in general payments, 2019–2025

Across 692 payments — averaging $15.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Lilly USA, LLC$964
  • Boehringer Ingelheim$892
  • Abbott$858
  • AstraZeneca$781
  • Corcept Therapeutics$681
  • plus $5K from 45 others

What the payments were for

  • Food & beverage$10,922100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$10,933 in reported general payments places this provider in the 95th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$56,251
Medicare patients
182
Services billed
1,203

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide321$488,589
JardianceEmpagliflozin234$263,317
MounjaroTirzepatide203$241,569
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog186$226,430
TrulicityDulaglutide117$207,172
FarxigaDapagliflozin Propanediol109$116,686
Tresiba Flextouch U-100Insulin Degludec76$98,192
Tresiba Flextouch U-200Insulin Degludec47$84,477
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog30$80,378
Humalog Kwikpen U-100Insulin Lispro145$70,785
RybelsusSemaglutide41$69,590
Lantus SolostarInsulin Glargine,hum.Rec.Anlog203$51,662
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/750$48,760
Repatha SureclickEvolocumab26$41,124
Novolog FlexpenInsulin Aspart101$38,709

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Novolog, Fiasp$1,335$586,722399 claims
Lilly USA, LLCMounjaro, Trulicity, Humalog$964$479,033384 claims
Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr$892$287,812261 claims
AstraZenecaFarxiga$781$116,686109 claims
AmgenProlia$259$21,49712 claims
MerckJanuvia$204$17,63614 claims
Sanofi-aventis U.S. LLCLantus$232$8,35333 claims
AbbVieSynthroid$388$4,75775 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,392 family providers in Indiana.

Other family in Fort Wayne

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →